Rigel Pharmaceuticals (RIGL) Assets Average (2011 - 2026)

Rigel Pharmaceuticals has reported Assets Average for 16 years, with the latest figure at $509.1 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 199.52% year-over-year to $509.1 million; the trailing twelve-month figure through Mar 2026 stood at $509.1 million (up 199.52% YoY), and the FY2025 full-year result was $338.8 million, up 140.96% from the prior year.
• Assets Average for Q1 2026 stood at $509.1 million, up from $378.1 million in the prior quarter.
• The five-year high for Assets Average was $509.1 million in Q1 2026, with the low at $116.2 million in Q3 2023.
• Average Assets Average over 5 years is $178.4 million, with a median of $133.9 million recorded in 2024.
• Year-over-year, Assets Average slumped 37.23% in 2022 and surged 199.52% in 2026.
• Tracing RIGL's Assets Average over 5 years: stood at $124.9 million in 2022, then slipped by 6.94% to $116.3 million in 2023, then soared by 30.46% to $151.7 million in 2024, then jumped by 149.22% to $378.1 million in 2025, then soared by 34.66% to $509.1 million in 2026.
• The last three Assets Average figures came in at $509.1 million (Q1 2026), $378.1 million (Q4 2025), and $224.6 million (Q3 2025), per Business Quant data.

Peer Comparison